On October 28, gtja research reports pointed out that jiangsu hengrui pharmaceuticals (600276.SH) Q3 revenue, net income attributable to shareholders, non-net income attributable to shareholders were 6.589 billion, 1.188 billion, 1.126 billion yuan, with a year-on-year increase of +12.72%, +1.91%, +0.84%, showing steady performance growth. The period of innovation and upgrade has entered the harvest period, which is expected to accelerate performance. Products are gradually going global, and the international layout is accelerating realization. Increased investment in research and development, good control of sales & management expenses ratio. Maintain a 'shareholding' rating.